INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,500 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
MA
Mahdessian AraDirector, Chief Executive Officer
TTANServiceTitan, Inc.
Derivative conversion · 10b5-1 plan
C—
32.0K sh
Jan 15, 2026Jan 15, 2026
Page 1476 of 1813
← PrevNext →
traded Jan 15, 2026
+0d
SEC Form 4

Evidence

0
Yuan Eric S.Director, Chief Executive Officer
ZMZoom Communications, Inc.
Derivative conversion · 10b5-1 plan
C—
12.1K sh
Jan 13, 2026Jan 15, 2026
traded Jan 13, 2026
+2dSEC Form 4

Evidence

51
FP
Feinberg PeterDirector
IMRXImmuneering Corp
Open-market purchase
BUY$87K
20.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

49
HD
Hildebrandt John DPresident and COO
PSMTPRICESMART INC
Open-market sale
SELL$1.02M
7,421 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

48
DA
DiGravio Karen AnnTrustee
GLQClough Global Equity Fund
Open-market purchase
BUY$3,062
378 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

46
KP
Kovaleski PaulEVP-Chief Merch. Officer
PSMTPRICESMART INC
Open-market sale
SELL$582K
4,255 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

46
IV
Infante Beatriz VDirector
PSMTPRICESMART INC
Open-market sale
SELL$273K
1,995 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

44
BR
Brumana RodrigoChief Financial Officer
JOBYJoby Aviation, Inc.
Open-market sale
SELL$7,756
523 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

43
BL
Baller LanceDirector, 10% Owner
GBCSSELECTIS HEALTH, INC.
Open-market purchase
BUY$14K
6,192 sh
Dec 18, 2025Jan 14, 2026
traded Dec 18, 2025
+27dSEC Form 4

Evidence

43
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Open-market sale
SELL$2.15M
140.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

43
DP
Duffy Sean P.Director, Chief Executive Officer
OMDAOmada Health, Inc.
Open-market sale
SELL$1.45M
90.5K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

40
BC
Billingsley ChesterDirector, Chief Executive Officer, 10% Owner
MNTRMentor Capital, Inc.
Open-market purchase
BUY$204K
11 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

40
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$1.37M
49.8K sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$148K
405 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
JC
Janks Leon CDirector
PSMTPRICESMART INC
Open-market sale
SELL$205K
1,499 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
FM
Frank MalcolmDirector
FDSFACTSET RESEARCH SYSTEMS INC
Open-market sale
SELL$452K
1,527 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
JC
Janks Leon CDirector
PSMTPRICESMART INC
Open-market sale
SELL$207K
1,501 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$63K
170 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
BJ
Bricker JudeDirector, Chief Executive Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$89K
5,062 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$63K
176 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$81K
226 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$65K
181 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$133K
365 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$102K
284 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$56K
156 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

39
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

38
DA
DiGravio Karen AnnTrustee
GLOClough Global Opportunities Fund
Open-market purchase
BUY$1,274
213 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

38
AE
Allison EricChief Product Officer
JOBYJoby Aviation, Inc.
Open-market sale
SELL$319K
21.5K sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

38
DA
DiGravio Karen AnnTrustee
GLVClough Global Dividend & Income Fund
Open-market purchase
BUY$774
124 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

37
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$283K
10.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

37
SR
Soule Randy10% Owner
SAFXXCF Global, Inc.
Open-market sale
SELL$34K
200.0K sh
Jan 8, 2026Jan 14, 2026
traded Jan 8, 2026
+6dSEC Form 4

Evidence

37
MC
Myles David C.CH. DISCOV. & NON-CLIN DEV OFF
OLMAOlema Pharmaceuticals, Inc.
Open-market sale
SELL$1.01M
35.0K sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence

37
BD
Baker Bruce DDirector
CMTVCOMMUNITY BANCORP /VT
Open-market purchase
BUY$5,040
180 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$9,361
25 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
BJ
Bevirt JoeBenDirector, CEO and Chief Architect, 10% Owner
JOBYJoby Aviation, Inc.
Open-market sale
SELL$24K
1,630 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence